Osimertinib in Early-Stage EGFR-Mutated Non-small Cell Lung Cancer: A Narrative Review of Its Impact on Survival, Safety, and Clinical Outcomes.

Lung cancer remains a significant global health issue, with early detection playing a critical role in improving patient outcomes. The treatment landscape for advanced non-small cell lung cancer (NSCLC) has evolved substantially, especially with the introduction of targeted therapies such as osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI). This narrative review examines the impact of osimertinib on survival rates in early-stage lung cancer and underscores the importance of early diagnosis and treatment initiation. We explore the genetic underpinnings of NSCLC, focusing on the role of EGFR mutations, and discuss the prevalence of early-stage lung cancer and the urgent need for timely intervention.  Additionally, the review assesses osimertinib's safety and efficacy in patients with early-stage EGFR-mutated lung cancer, drawing from a wide range of studies and clinical trials. Findings suggest that osimertinib has the potential to improve overall survival (OS) and progression-free survival (PFS) compared to traditional treatments such as chemotherapy, surgery, and first-generation EGFR-TKIs. The therapeutic profile of osimertinib is comprehensively analyzed, including its associated adverse events, clinical outcomes, and its impact on quality of life. We also address potential challenges with osimertinib, such as resistance mechanisms and the need for personalized treatment approaches. Despite these challenges, osimertinib emerges as a promising and well-tolerated treatment option for patients with EGFR mutations in early-stage lung cancer. The review highlights the importance of incorporating osimertinib into standard treatment regimens to improve patient outcomes and survival rates in early-stage lung cancer.